Cannabinoid hyperemesis syndrome in North America: evaluation of health burden and treatment prevalence.
Aliment Pharmacol Ther
; 56(11-12): 1532-1542, 2022 Dec.
Article
in English
| MEDLINE | ID: covidwho-2097701
ABSTRACT
BACKGROUND:
Cannabinoid hyperemesis syndrome (CHS) is a poorly understood vomiting disorder associated with chronic cannabis use.AIMS:
To characterise patients experiencing CHS in North America and to obtain a population-based estimate of CHS treatment prevalence in Canada before and during the Covid-19 pandemicMETHODS:
Internet survey of 157 CHS sufferers in Canada and the United States. Administrative health databases for the province of Alberta (population 5 million) were accessed to measure emergency department (ED) visits for vomiting, with a concurrent diagnostic code for cannabis use. Three time periods of 1 year were assessed prior to recreational cannabis legalisation (2017-2018), after recreational legalisation (2018-2019) and during the first year of the Covid-19 pandemic (2020-2021).RESULTS:
Problematic cannabis use (defined as a CUDIT-R score ≥8) was universal among the survey cohort, and 59% and 68% screening for moderate or worse anxiety or depression, respectively. The overall treatment prevalence of CHS across all ages increased from 15 ED visits per 100,000 population (95% CI, 14-17) prior to legalisation, to 21 (95% CI, 20-23) after legalisation, to 32 (95% CI, 31-35) during the beginning of the Covid-19 pandemic (p < 0.001). Treatment prevalence among chronic cannabis users was as high as 6 per 1000 in the 16-24 age group.CONCLUSION:
Survey data suggest patients with CHS almost universally suffer from a cannabis use disorder, which has significant treatment implications. Treatment prevalence in the ED has increased substantially over a very short time period, with the highest rates seen during the Covid-19 pandemic.
Full text:
Available
Collection:
International databases
Database:
MEDLINE
Main subject:
Cannabinoids
/
COVID-19
Type of study:
Cohort study
/
Diagnostic study
/
Experimental Studies
/
Observational study
/
Prognostic study
Limits:
Humans
Country/Region as subject:
North America
Language:
English
Journal:
Aliment Pharmacol Ther
Journal subject:
Pharmacology
/
Gastroenterology
/
Drug Therapy
Year:
2022
Document Type:
Article
Affiliation country:
Apt.17265
Similar
MEDLINE
...
LILACS
LIS